Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 14, 2004; DOI: 10.1124/jpet.103.062562
0022-3565/04/3091-165-172$20.00
JPET 309:165-172, 2004
CARDIOVASCULAR
Characterization of the Contractile 5-Hydroxytryptamine Receptor in the Renal Artery of the Normotensive Rat
Stephanie W. Watts, and
Janice M. Thompson
Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan
Our goal was to characterize the 5-hydroxytryptamine (5-HT) receptor(s) mediating contraction in the isolated right renal artery, testing the hypothesis that the 5-HT2A receptor would be the primary and likely only 5-HT receptor involved in contraction. Contraction of arteries was investigated in isolated tissue baths, and expression of 5-HT receptors was measured using immunohistochemical and Western analyses. Compared with endothelium-denuded rat aorta, a tissue with an established 5-HT2A receptor, endothelium-denuded renal artery contracted to 5-HT with a 10-fold greater potency. Surprisingly, the 5-HT2B receptor agonist
-methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine hydrochloride (BW723C86) caused a concentration-dependent contraction that was antagonized by the 5-HT2B receptor antagonist 6-methyl-1,2,3,4-tetrahydro-1-[3,4-dimethoxyphenyl) methyl-9H-pyrido[3,4b]indole] hydrochloride (LY272015) and nonselective 5-HT2 receptor antagonist 6-methyl-1-(1-methylethyl)-ergoline-8b-carboxylic acid 2-hydroxy-1-methylpropyl ester maleate (LY53857). Correlation of -log EC50 values with binding affinities (pKi) indicated that contraction of the renal artery elicited by 13 different agonists was likely consistent with activation of a 5-HT2A (r = 0.928) and 5-HT2B (r = 0.843) receptor. 5-HT-induced contraction was shifted by the 5-HT2A receptor antagonist ketanserin (3 and 10 nM) and the 5-HT2B receptor antagonist LY272015 (10 and 50 nM). Higher than expected concentrations of the 5-HT2A/5-HT2B receptor antagonist LY53857 were needed to antagonize 5-HT-induced contraction and the 5-HT2B receptor antagonist 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine (RS127445) was virtually inactive. Western and immunohistochemical analyses of the renal artery validated the presence of 5-HT2A and 5-HT2B receptor protein. These results suggest that the renal artery possesses a complex 5-HT receptor population, including ketanserin- and LY272015-sensitive receptors. This unique pharmacology may reflect differences in 5-HT receptor coupling between tissues or heterogeneity in the subtype(s) of 5-HT receptors expressed in the renal artery.
Received for publication
November 5, 2003
Accepted
December 8, 2003.
Address correspondence to: Dr. Stephanie W. Watts, Department of Pharmacology and Toxicology, B445 Life Sciences Bldg., Michigan State University, East Lansing, MI 48824-1317. E-mail: wattss{at}msu.edu
This article has been cited by other articles:

|
 |

|
 |
 
C. Collet, C. Schiltz, V. Geoffroy, L. Maroteaux, J.-M. Launay, and M.-C. de Vernejoul
The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation
FASEB J,
February 1, 2008;
22(2):
418 - 427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Malacarne, S. Moll, K. Hadaya, L. Buhler, and P.-Y. Martin
Renal ischaemic injuries during the use of zolmitriptan for treatment of migraines in a transplanted patient under tacrolimus therapy
Nephrol. Dial. Transplant.,
November 1, 2007;
22(11):
3341 - 3343.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Linder, W. Ni, J. L. Diaz, T. Szasz, R. Burnett, and S. W. Watts
Serotonin (5-HT) in Veins: Not All in Vain
J. Pharmacol. Exp. Ther.,
November 1, 2007;
323(2):
415 - 421.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.